- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03272295
A Nicotine Pharmacokinetics and Smoking Behaviour Study Examining Cigarette Ingredients
A Randomised, Controlled, Double-Blind Study to Examine Nicotine Pharmacokinetics and Smoking Behaviour in Healthy Smokers When Smoking Cigarettes Containing Different Commonly Used Ingredients
Study Overview
Status
Conditions
Intervention / Treatment
- Other: Reference cigarette
- Other: Cigarette with carob bean extract
- Other: Cigarette with cocoa powder
- Other: Cigarette with fenugreek extract
- Other: Cigarette with fig juice
- Other: Cigarette with glycerol
- Other: Cigarette with multiple ingredients
- Other: Cigarette with guaiacol
- Other: Cigarette with liquorice extract powder
- Other: Cigarette plus I-menthol
- Other: Cigarette with propylene glycol
- Other: Cigarette with sorbitol
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Northern Ireland
-
Belfast, Northern Ireland, United Kingdom, BT9 6AD
- Celerion
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Subjects will be:
1.1. males or females 1.2. 21 to 55 years of age, inclusive, demonstrated by appropriate proof of identification.
Subjects will have a:
2.1. BMI of 18.5 to 30.0 kg/m2, inclusive 2.2. body weight exceeding 52 kg (males) or 45 kg (females)
Subjects will be in good health, as judged by the PI or the appropriately qualified designee based on:
3.1. medical history 3.2. physical examination 3.3. vital signs assessment 3.4. 12-lead ECG 3.5. clinical laboratory evaluations 3.6. lung function tests
- Subjects will have given their written informed consent to participate in the study and will have agreed to abide by the study restrictions.
- Subjects must demonstrate the ability to comprehend the informed consent form (ICF), be able to communicate well with the PI or the appropriately qualified designee, understand and comply with the requirements of the study, and be judged suitable for the study in the opinion of the PI or the appropriately qualified designee.
- Subjects will be willing to refrain from consuming alcohol within 24 hours prior to Admission.
- Subjects will be regular smokers of factory made, non-menthol cigarettes whose chosen brand is within the ISO tar bands 6 to 10 mg, inclusive and should not change their usual brand cigarette for the duration of the study.
- Subjects will have smoked their chosen brand for a minimum of 6 months and will have smoked for at least 3 years prior to Screening, and will typically smoke at least 10 and a maximum of 30 CPD.
- Subjects must have a urine cotinine level >200 ng/mL and an ECO measurement of >10 ppm at Screening.
- Subjects will be willing to use the study products and smoke only the study products provided to them during clinical confinement and to abstain from smoking when required.
Exclusion Criteria:
- Male subjects who do not agree, or whose partners of childbearing potential do not agree, to use a barrier method of contraception (i.e., a condom with spermicide) in addition to a second highly effective method of contraception used by their female partners or to refrain from donating sperm from Admission for Visit 1 until 5-7 days after Discharge.
- Female subjects of childbearing potential who do not agree to use a highly effective method of birth control in conjunction with male barrier method contraception (i.e., a condom with spermicide) from the time of signing the ICF until 5-7 days after Discharge.
- Female subjects who are pregnant or breastfeeding. This will be confirmed at Screening and at each Admission. Any female subject who becomes pregnant during this study will be withdrawn.
Subjects who have donated:
4.1. ≥450 mL of blood within 90 days prior to Admission 4.2. plasma in the 7 days prior to Admission 4.3. platelets in the 6 weeks prior to Admission
- Subjects who have an acute illness (e.g., upper respiratory tract infection, viral infection, etc.) requiring treatment within 4 weeks prior to Admission.
- Subjects who have used any nicotine or tobacco product other than commercially manufactured non-menthol, filter cigarettes within 14 days of Screening.
- Subjects who are self-reported non-inhalers (smokers who draw smoke from the cigarette into the mouth and throat but who do not inhale). Subjects who are determined as non-inhalers at Screening will be excluded.
- Subjects who, prior to enrolment, are planning to quit smoking in the next 12 months of Screening. All subjects will be informed that they are free to quit smoking and withdraw from the study at any time. Any subject who decides to quit smoking will be directed to appropriate stop smoking services
- Subjects who have a significant history of alcoholism or drug/chemical abuse within 24 months prior to Screening, as determined by the PI or the appropriately qualified designee.
- Subjects who have a positive urine drugs of abuse or alcohol screen (confirmed by repeat) at Screening or Admission.
Subjects who:
11.1. have serum hepatitis 11.2. are carriers of the hepatitis B surface antigen (HBsAg) 11.3. are carriers of the hepatitis C antibody 11.4. have a positive result for the test for human immunodeficiency virus (HIV) antibodies.
- Subjects who have used prescription or OTC bronchodilator medication (e.g., inhaled or oral β-adrenergic agonists) to treat a chronic condition within the 12 months prior to the first Admission (Visit 1) and throughout the study.
Subjects who have received any medications or substances (other than tobacco) which:
13.1. are known to be strong inducers or inhibitors of CYP enzymes within 14 days or 5 half-lives of the drug (whichever is longer) prior to the first Admission (Visit 1) and throughout the study.
- Subjects who are planning to undergo significant lifestyle changes during the study e.g., big change in exercise levels.
- Subjects who are unable to communicate effectively with the PI/study staff (i.e., language problem, poor mental development, or impaired cerebral function).
- Subjects who are unwilling or unable to comply with the study requirements.
- Employees, and immediate relatives, of the tobacco industry or the clinical site.
- Subjects who are still participating in another clinical study (e.g., attending follow-up visits) or who have participated in a clinical study involving administration of an investigational drug (new chemical entity) in the past 3 months prior to first Admission (Visit 1).
- Subjects who have any clinically relevant abnormal findings on the physical examination, medical history, ECG, lung function tests (forced expiratory volume in 1 second/ forced vital capacity [FEV1/FVC]), or clinical laboratory panel, unless deemed not clinically significant by the PI or the appropriately qualified designee.
- Subjects who have, or who have had a history of, any clinically significant neurological, gastrointestinal, renal (including urinary tract infection or nephrolithiasis), hepatic, cardiovascular, psychiatric, respiratory, metabolic, endocrine, haematological or other major disorder that, in the opinion of the PI or the appropriately qualified designee, would jeopardise the safety of the subject or impact on the validity of the study results.
- Subjects who have previously been diagnosed with any form of malignancy.
- Subjects who have any clinically significant abnormal laboratory safety findings at Screening and prior to first product use, as determined by the PI or the appropriately qualified designee (1 repeat assessment is acceptable).
- Subjects who have previously been randomised into or withdrawn from this study.
- Subjects who, in the opinion of the PI or the appropriately qualified designee, should not participate in this study.
Compliance with all inclusion and exclusion criteria will be reaffirmed at each study Visit.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A
Reference product (product 1) x 2, Single ingredients products 2, 3, 4, 5, 6 and Multiple ingredient product (product 12).
Single cigarette each for nicotine PK assessment and smoking behaviour assessment.
|
The reference product is based on a commercially-available king-size cigarette design (length 83 mm, circumference 24.6 mm) with a single segment cellulose acetate filter and tobacco blend recipe without ingredients.
Based on reference cigarette with added ingredient
Based on reference cigarette with added ingredient
Based on reference cigarette with added ingredient
Based on reference cigarette with added ingredient
Based on reference cigarette with added ingredient
Based on reference cigarette plus propylene glycol, glycerol, liquorice extract powder, cocoa powder, carob bean extract, fig juice concentrate, maltol, guaiacol, geraniol, fenugreek extract.
|
Experimental: Arm B
Reference product (product 1), Single ingredients products 7, 8, 9, 10, 11 and Multiple ingredient product (product 12).
Single cigarette each for nicotine PK assessment and smoking behaviour assessment.
|
The reference product is based on a commercially-available king-size cigarette design (length 83 mm, circumference 24.6 mm) with a single segment cellulose acetate filter and tobacco blend recipe without ingredients.
Based on reference cigarette plus propylene glycol, glycerol, liquorice extract powder, cocoa powder, carob bean extract, fig juice concentrate, maltol, guaiacol, geraniol, fenugreek extract.
Based on reference cigarette with added ingredient
Based on reference cigarette with added ingredient
Based on reference cigarette with added ingredient
Based on reference cigarette with added ingredient
Based on reference cigarette with added ingredient
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax
Time Frame: -5, 1, 2, 3, 4, 5, 6, 7, 8, 15, 60, 120, 180 and 240 minutes in relation to the first puff
|
To assess the maximum nicotine concentration when subjects smoke a single cigarette
|
-5, 1, 2, 3, 4, 5, 6, 7, 8, 15, 60, 120, 180 and 240 minutes in relation to the first puff
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUC0-last
Time Frame: -5, 1, 2, 3, 4, 5, 6, 7, 8, 15, 60, 120, 180 and 240 minutes in relation to the first puff
|
To assess the area under the concentration curve from time 0 to last the time-point when subjects smoke a single cigarette
|
-5, 1, 2, 3, 4, 5, 6, 7, 8, 15, 60, 120, 180 and 240 minutes in relation to the first puff
|
Tmax
Time Frame: -5, 1, 2, 3, 4, 5, 6, 7, 8, 15, 60, 120, 180 and 240 minutes in relation to the first puff
|
To assess the time to maximum nicotine concentration when subjects smoke a single cigarette
|
-5, 1, 2, 3, 4, 5, 6, 7, 8, 15, 60, 120, 180 and 240 minutes in relation to the first puff
|
Puff Volume
Time Frame: During the time required to smoke a single cigarette (up to 8 minutes)
|
To assess puff volume when subjects smoke a single cigarette
|
During the time required to smoke a single cigarette (up to 8 minutes)
|
Puff duration
Time Frame: During the time required to smoke a single cigarette (up to 8 minutes)
|
To assess puff duration when subjects smoke a single cigarette
|
During the time required to smoke a single cigarette (up to 8 minutes)
|
Number of puffs
Time Frame: During the time required to smoke a single cigarette (up to 8 minutes)
|
To assess number of puffs when subjects smoke a single cigarette
|
During the time required to smoke a single cigarette (up to 8 minutes)
|
Inhalation volume
Time Frame: During the time required to smoke a single cigarette (up to 8 minutes)
|
To assess inhalation volume when subjects smoke a single cigarette
|
During the time required to smoke a single cigarette (up to 8 minutes)
|
Exhalation volume
Time Frame: During the time required to smoke a single cigarette (up to 8 minutes)
|
To assess exhalation volume when subjects smoke a single cigarette
|
During the time required to smoke a single cigarette (up to 8 minutes)
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Johnston Stewart, MB, Celerion GB Ltd
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BAT1117009
- CA21208 (Other Identifier: Celerion GB Ltd)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Smoking
-
University of Southern CaliforniaAmerican Cancer Society, Inc.CompletedSmoking | Smoking Cessation | Smoking, Cigarette | Smoking Behaviors | Cessation, SmokingUnited States
-
University of VirginiaRecruitingSmoking | Smoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking, Cigarette | Quitting SmokingUnited States
-
Columbia UniversityNational Cancer Institute (NCI)RecruitingSmoking | Smoking Cessation | Smoking Reduction | Smoking BehaviorsUnited States
-
National Cancer Institute (NCI)CompletedSmoking | Smoking Cessation | Cigarette Smoking | Tobacco, SmokingUnited States
-
University GhentRecruitingSmoking | Smoking Tobacco | Smoking Prevention | Smoking CigaretteBelgium
-
Medical University of South CarolinaCompletedSmoking | Smoking Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
Maastricht UniversityThe Investigative Desk; SEO Amsterdam Economics; IVO Research InstituteEnrolling by invitationSmoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking BehaviorsNetherlands
-
Jennifer Marler, MDCompletedSmoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking BehaviorsUnited States
-
Medical University of South CarolinaRecruitingSmoking | Smoking Cessation | Tobacco Smoking | Cigarette SmokingUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI); University of Massachusetts, WorcesterRecruiting
Clinical Trials on Reference cigarette
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaFondazione Salvatore MaugeriCompleted
-
Medical University of ViennaUnknown
-
University of California, San FranciscoNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH); Roswell Park Cancer InstituteCompleted
-
GWT-TUD GmbHTerminated
-
Massachusetts General HospitalWithdrawn
-
Virginia Commonwealth UniversityCompletedElectronic CigarettesUnited States
-
Virginia Polytechnic Institute and State UniversityNational Cancer Institute (NCI); University of MinnesotaCompletedTobacco Use DisorderUnited States
-
Abramson Cancer Center of the University of PennsylvaniaCompleted
-
Virginia Commonwealth UniversityNational Institute on Drug Abuse (NIDA); Penn State University; Food and Drug...CompletedNontherapeuticUnited States
-
Masonic Cancer Center, University of MinnesotaOhio State UniversityActive, not recruiting